Proof of concept studies for tissue-protective agents in multiple sclerosis

Area of Science:

• Neuroscience
• Clinical Trials
• Immunology

Background:

• Multiple sclerosis (MS) research shows significant interest in treatments that protect tissue.
• Developing effective disease-modifying therapies for MS remains a critical clinical challenge.

Purpose of the Study:

• To discuss and propose optimal study designs for proof-of-concept trials evaluating tissue-protective agents in multiple sclerosis.
• To leverage existing data and assessment methodologies for designing future clinical investigations.

Main Methods:

• Convened a group of multiple sclerosis (MS) clinical trialists and researchers.
• Discussed and favored a specific study design for proof-of-concept investigations.
• Considered various assessment methods and data available for trial design.

Main Results:

• The favored design is a randomized, double-blind, parallel-group study comparing active treatment to placebo.
• The primary endpoint focuses on changes in brain volume measured from a 3-6 month post-baseline scan to a 1-year follow-up.
• Designing studies to reduce deficits after acute exacerbations is complex and depends on treatment onset speed.

Conclusions:

• The proposed designs provide a framework for future clinical trials of tissue-protective agents in MS.
• Conducting these studies will generate essential longitudinal data.
• This data will refine endpoint selection, eligibility criteria, and sample size estimations for subsequent MS trials.